Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeJ&J Innovative Medicine Oncology

      J&J Innovative Medicine Oncology

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection

      In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.

      Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way

      The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.

      Are super-personalized solutions the future of healthcare?

      The goal of precision medicine is to develop individualized treatments based on a patient’s genetic profile. Here’s how Johnson & Johnson is harnessing this cutting-edge field of tailor-made medicine.

      Behind the relentless pursuit of multiple myeloma cures

      Johnson & Johnson has been dedicated to developing innovative treatments for blood cancers for nearly 20 years. Scientist Kodandaram “Ram” Pillarisetti is at the forefront of the company’s commitment to working toward its goal of one day eliminating the disease.

      By the numbers: Helping to reduce disparities in cancer care

      For World Health Day, learn how Johnson & Johnson’s commitment to Diversity, Equity and Inclusion is helping to deliver transformational cancer treatments and solutions that reach the patients who need them most.

      Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list.

      A commitment to social responsibility and innovation are just two of the attributes that helped the company land a spot on the prestigious list once again.

      5 things we now know about multiple myeloma

      Rates of this blood cancer have jumped more than 125% worldwide since the 1990s. But there’s reason to have hope: Today, life expectancy has at least doubled in some cases. That’s thanks to increased research, new learnings and innovative advances—and Johnson & Johnson is at the forefront of this crucial work.

      Could these 3 researchers transform the fates of patients with multiple myeloma?

      For National Cancer Prevention Month, we’re spotlighting three leading Johnson & Johnson female hematologists—innovators who are not only saving lives and advancing new treatments but also paving the way for the next generation of women in their field.

      “I’m working to develop better treatments for children with devastating diseases”

      A life-threatening condition that afflicts young cancer patients. A rare and painful form of pediatric arthritis. Learn about how Johnson & Johnson is innovating to use existing medications to help kids with these illnesses—and meet two women on the forefront of this game-changing work.